This opportunity uses the U01 Research Project – Cooperative Agreements funding mechanism.
The National Institute of Diabetes and Digestive and Kidney Diseases invites applications for its human islet research network (HIRN) – consortium on targeting and regeneration (CTAR) (UC4 clinical trial not allowed) funding opportunity. This supports the development of innovative strategies to increase or protect functional human beta cell mass in patients with type-1 diabetes through the controlled manipulation of beta cell replication, islet cell plasticity, and the reprogramming of pancreatic non-beta cells into beta-like cells, or through shielding the residual beta cell mass from the autoimmune environment.
Examples of eligible activities include the discovery, development or optimisation of screening platforms, novel receptors or transmembrane proteins, reagents or molecular complexes, therapeutic molecules, and cell engineering and targeting.
Projects that mostly focus on developing delivery vehicles or cell-targeting strategies need to demonstrate efficacy of delivery to the human islet environment in-vivo using biological or imaging-based readouts. Projects exclusively focusing on developing new imaging-based strategies for in-vivo monitoring of beta cell mass or function are not eligible.
Funding & Duration
The total budget for the financial year 2019 is USD $2.5M (approx. AUD $3.5M), to fund three to five awards. Application budgets are limited to USD $550,000 (approx. AUD $763,000) per year over a maximum period of four years.
Non-domestic (non-U.S.) Entities (Foreign Institutions) are eligible to apply.
Submission Requirements & Due Date
- Letter of Intent (LOI): 26 January 2019
- Applications submitted for internal review: 19 February 2019
- Please email email@example.com if you are considering applying for this scheme.
- See also: Submitting an Application to Research Services for Review